Press Releases

Date Title and Summary Additional Formats
Toggle Summary Dynavax Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
BERKELEY, CA -- (Marketwired) -- 08/15/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the completion of an underwritten public offering of 5,750,000 shares of its common stock, including 750,000 shares sold pursuant to the full exercise of an over-allotment option previously
View HTML
Toggle Summary Dynavax Prices Public Offering of Common Stock
BERKELEY, CA -- (Marketwired) -- 08/09/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the pricing of a previously announced underwritten public offering of 5,000,000 shares of its common stock, offered at a price to the public of $15.00 per share.
View HTML
Toggle Summary Dynavax Announces Proposed Public Offering of Common Stock
BERKELEY, CA -- (Marketwired) -- 08/08/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it intends to offer and sell $125.0 million of shares of its common stock, subject to market and other conditions, in an underwritten public offering.
View HTML
Toggle Summary Dynavax Provides U.S. Regulatory Update on HEPLISAV-B(TM) Following FDA Advisory Committee Meeting
Conference call today at 4:30 p.m. EDT
View HTML
Toggle Summary Dynavax Reports Second Quarter 2017 Financial Results
BERKELEY, CA -- (Marketwired) -- 08/02/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the second quarter ended June 30, 2017 . Cash, cash equivalents and marketable securities were $127.0 million at June 30, 2017 compared to $81.4 million at December 31,
View HTML
Toggle Summary Dynavax Announces FDA Advisory Committee Vote in Favor of HEPLISAV-B(TM)
BERKELEY, CA -- (Marketwired) -- 07/28/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 12 to 1 that the safety data for HEPLISAV-B [Hepatitis B
View HTML
Toggle Summary Dynavax Presents Updated Data for SD-101 in Combination with KEYTRUDA(R) (pembrolizumab) Highlighting an ORR in 7 out of 7 Patients Naive to an Anti-PD-1 or Anti-PD-L1 Therapy
Data Presented at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
View HTML
Toggle Summary Dynavax to Present Data on SD-101 in Combination with KEYTRUDA(R) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
BERKELEY, CA -- (Marketwired) -- 05/19/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that updated data from an ongoing Phase 1b/2 study investigating SD-101, Dynavax's intratumoral TLR9 agonist, in combination with KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy developed by
View HTML
Toggle Summary Dynavax Reports First Quarter 2017 Financial Results
BERKELEY, CA -- (Marketwired) -- 05/08/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the first quarter ended March 31, 2017 . Cash, cash equivalents and marketable securities were $85.4 million at March 31, 2017 compared to $81.4 million at December 31,
View HTML
Toggle Summary Dynavax Announces FDA Advisory Committee Meeting to Review HEPLISAV-B
Meeting Scheduled for July 28, 2017
View HTML